See more : TeraGo Inc. (TRAGF) Income Statement Analysis – Financial Results
Complete financial analysis of BetterLife Pharma Inc. (BETR.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BetterLife Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Asahi Concrete Works Co., Ltd. (5268.T) Income Statement Analysis – Financial Results
- Mueller Water Products, Inc. (MWA) Income Statement Analysis – Financial Results
- XWELL, Inc. (XWEL) Income Statement Analysis – Financial Results
- AGBA Acquisition Limited (AGBA) Income Statement Analysis – Financial Results
- Face Up Entertainment Group, Inc. (FUEG) Income Statement Analysis – Financial Results
BetterLife Pharma Inc. (BETR.CN)
About BetterLife Pharma Inc.
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 18.44K | 18.44K | 22.81 | 85.90 | 1.14M | 32.39K | 0.00 | 417.39 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K |
| Gross Profit | 0.00 | -18.44K | -18.44K | -22.81 | -85.90 | -1.14M | -32.39K | 0.00 | -417.39 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 570.95K | 2.68M | 5.42M | 284.70K | 63.77K | 364.78K | 86.74K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.04K | 0.00 | 1.63K | 112.48K |
| General & Administrative | 1.20M | 6.44M | 4.09M | 7.37M | 7.64M | 3.60M | 1.04M | 7.58M | 11.99M | 81.41K | 45.40K | 89.24K | 300.47K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.44M | 123.22K | 437.69K | 185.95K | 96.64K | 11.08K | 0.00 | 54.21K | 0.00 | -9.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.64M | 6.56M | 4.53M | 7.56M | 7.74M | 5.22M | 1.04M | 7.64M | 11.99M | 71.42K | 45.40K | 89.24K | 300.47K | 142.19K | 117.34K | 40.76K |
| Other Expenses | 30.35K | 18.14K | 26.93K | -40.36K | 48.38K | -8.86K | -10.80K | 0.00 | 450.08 | 455.00 | 455.00 | 455.00 | 455.00 | 38.00 | 0.00 | 0.00 |
| Operating Expenses | 3.24M | 9.26M | 9.97M | 7.95M | 9.20M | 5.59M | 1.16M | 7.64M | 11.99M | 71.88K | 45.86K | 89.69K | 358.97K | 142.23K | 118.96K | 153.24K |
| Cost & Expenses | 3.24M | 9.26M | 9.97M | 7.95M | 9.20M | 6.73M | 1.16M | 7.64M | 11.99M | 71.88K | 45.86K | 89.69K | 358.97K | 142.23K | 118.96K | 653.24K |
| Interest Income | 0.00 | 67.18 | 58.35 | 265.00 | 4.48K | 4.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 50.90K | 67.18K | 58.35K | 40.10K | 428.78K | 1.08K | 33.79K | 15.28K | 0.00 | 224.75K | 98.13K | 24.34K | 368.13K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 18.44K | 18.44K | 18.44K | 342.81K | 1.41M | 1.14M | 32.39K | 418.97 | 450.08 | 455.00 | 455.00 | 455.00 | 455.00 | 38.00 | 1.17K | 526.00 |
| EBITDA | -3.19M | -9.24M | -9.95M | -7.83M | -17.40M | -6.88M | 47.36K | -8.16M | -11.99M | -71.42K | -45.40K | 461.98K | 1.88M | -3.01M | -117.79K | -652.71K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.24M | -9.46M | -10.21M | -7.92M | -18.73M | -6.73M | -1.29M | -7.89M | -12.01M | -130.81K | -76.89K | -88.89K | -362.51K | -144.34K | -118.96K | -653.24K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 341.73K | 87.88K | -1.78M | -28.44M | -10.25M | -2.53M | 1.21M | -430.04K | 20.16K | -1.11M | -676.99K | 430.32K | 1.78M | -2.88M | -1.17K | -526.00 |
| Income Before Tax | -2.90M | -9.37M | -11.99M | -36.35M | -19.59M | -9.25M | -149.50K | -8.23M | -11.99M | -1.00M | -753.88K | 341.43K | 1.42M | -3.02M | -120.13K | -653.76K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -271.26K | 166.67K | -258.00 | 477.16K | -160.24K | 22.99K | -148.24K | 0.00 | 224.75K | 98.13K | 24.34K | 368.13K | 2.88M | 0.00 | 0.00 |
| Net Income | -2.89M | -9.02M | -12.16M | -36.35M | -19.59M | -9.25M | -149.50K | -8.23M | -11.99M | -1.00M | -753.88K | 341.43K | 1.42M | -3.02M | -120.13K | -653.76K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.10 | -0.16 | -1.34 | -1.30 | -1.03 | -0.02 | -1.09 | -1.54 | -0.86 | -0.16 | 0.10 | 0.42 | -1.08 | -0.05 | -0.30 |
| EPS Diluted | -0.03 | -0.10 | -0.16 | -1.34 | -1.30 | -1.03 | -0.02 | -1.09 | -1.54 | -0.86 | -0.16 | 0.02 | 0.22 | -1.08 | -0.05 | -0.30 |
| Weighted Avg Shares Out | 109.29M | 86.56M | 75.47M | 27.03M | 15.04M | 9.02M | 7.99M | 7.53M | 7.77M | 1.16M | 4.83M | 3.58M | 3.39M | 2.80M | 2.38M | 2.19M |
| Weighted Avg Shares Out (Dil) | 109.29M | 86.56M | 75.47M | 27.03M | 15.04M | 9.02M | 7.99M | 7.53M | 7.77M | 1.16M | 4.83M | 17.04M | 6.53M | 2.80M | 2.38M | 2.19M |
Source: https://incomestatements.info
Category: Stock Reports